[
  {
    "ts": null,
    "headline": "Freedom Capital Upgrades Abbott Laboratories (ABT) to Buy",
    "summary": "​Abbott Laboratories (NYSE:ABT) is one of the Best 52-Week Low Stocks to Invest In. On January 29, Freedom Capital upgraded the stock from Hold to Buy, but lowered the price target from $130 to $120. Earlier, on January 23, UBS reiterated a Buy rating on the stock with a $158 price target. ​The positive ratings […]",
    "url": "https://finnhub.io/api/news?id=b63c140a8734de35475e7fbec0667be2a5171ffc764d6f1e9ff2f6774ca71744",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1769931528,
      "headline": "Freedom Capital Upgrades Abbott Laboratories (ABT) to Buy",
      "id": 138322055,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "ABT",
      "source": "Yahoo",
      "summary": "​Abbott Laboratories (NYSE:ABT) is one of the Best 52-Week Low Stocks to Invest In. On January 29, Freedom Capital upgraded the stock from Hold to Buy, but lowered the price target from $130 to $120. Earlier, on January 23, UBS reiterated a Buy rating on the stock with a $158 price target. ​The positive ratings […]",
      "url": "https://finnhub.io/api/news?id=b63c140a8734de35475e7fbec0667be2a5171ffc764d6f1e9ff2f6774ca71744"
    }
  }
]